Skip to content

Insider · CIK 0001854586

Yu-Waye Chu

officer

Files at CTMX (CytomX Therapeutics, Inc.). First filing Mar 20, 2025, latest Mar 19, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $139k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

CTMX: CytomX Therapeutics, Inc.

CTMXOct 9, 2026 · close 2.57

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
46Moderate
CTMXsell 4
CytomX Therapeutics, Inc.
$137k
21,279 shares
-10%+1162% from low-19% from high
30Weak
CTMXsell 5
CytomX Therapeutics, Inc.
$2,411
4,025 shares
-3%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Mar 17, 2026CTMX
CytomX Therapeutics, Inc.
SOpen-market sale
Common Stock
-21,279$6.42$137k189,446Mar 19, 2026
Feb 2, 2026CTMX
CytomX Therapeutics, Inc.
AGrant or award
Common Stock
+75,000$0.00$0210,725Feb 4, 2026
Feb 2, 2026CTMX
CytomX Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+300,000$0.00$0300,000Feb 4, 2026
Sep 26, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+87,500$0.00$087,500Sep 30, 2025
Sep 26, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Performance Stock Units (PSUs)derivative
+43,750$0.00$043,750Sep 30, 2025
Mar 18, 2025CTMX
CytomX Therapeutics, Inc.
SOpen-market sale
Common Stock
-4,025$0.60$2,411135,725Mar 20, 2025
Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Common Stock
+56,000$0.00$082,250Feb 6, 2025
Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Common Stock
+57,500$0.00$0139,750Feb 6, 2025
Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+238,000$0.00$0238,000Feb 6, 2025
Feb 4, 2025CTMX
CytomX Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+115,000$0.00$0115,000Feb 6, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Yu-Waye Chu: insider trades and track record | InsiderTell